Campaigners have welcomed support from the pharmaceutical industry for a global drive against antibiotic resistance, announced today.
Some 80 pharmaceutical companies have signed a declaration to be launched at the World Economic Forum in Davos, Switzerland.
The companies agree that they should help to stop incentives that lead to large volume prescription of antibiotics.
But they also call on governments to look at the pricing of antibiotics and finance for research and development.
They say the profitability of new antibiotics should not depend on the volume sold.
Lord Jim O’Neill, who is heading a UK review of the subject, said the declaration was “a major step forward.”
He said: "The pharmaceutical industry, as well as society at large, cannot afford to ignore the threat of antibiotic resistance, so I commend those companies who have signed the declaration for recognising the long-term importance of revitalising research and development in antibiotics, and for their leadership in overcoming the difficult issues of collective action at play here."
It was also welcomed by Professor Colin Garner, chief executive of Antibiotic Research UK.
He said: “It will be many years before any real progress can be made since it takes 15 to 20 years to develop a new drug and costs £100’s of millions. On the other hand, the problem of antibiotic resistance is here and now and getting worse.
“We have been far too cavalier in the use of the precious antibiotics we have and we need as a matter of urgency to see a dramatic reduction in antibiotic prescribing.”

Leave a Reply